All In Biotech

Free tool

FAERS Monitor: Locametz

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215841 or its brand name (Locametz, Gallium Ga-68 Gozetotide). Reports on generic versions are filed under their own applications.

Reports

45

Serious

35

78% of reports

Hospitalization

25

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • anaemia3
  • alanine aminotransferase increased2
  • bone marrow failure2
  • dyspnoea2
  • expired product administered2
  • febrile neutropenia2
  • pancytopenia2
  • sciatica2
  • skin infection2
  • agitation1
  • agranulocytosis1
  • amylase increased1
  • arthralgia1
  • aspartate aminotransferase increased1
  • aspiration1

Reports by year received

View as table
YearReports
20227
202331
20244
20252
20261

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,114 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
amylase increased1126.718.231
skin infection283.321.591
sciatica258.715.163
bone marrow failure246.011.949
aspiration142.76.110
expired product administered228.17.329
agranulocytosis125.13.65
pancytopenia216.74.316
alanine aminotransferase increased215.23.914
febrile neutropenia214.13.613
aspartate aminotransferase increased18.81.31
anaemiaSignal37.42.511
agitation16.40.91
dyspnoea21.70.40
arthralgia11.10.20

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.